Search Results

June 11, 2020 13:20 UTC Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson PARIS--( BUSINESS WIRE )-- Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the sale of its portfolio company Corvidia Therapeutics to Novo Nordisk, for $2.1 bi

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.

Under terms of the deal, Novo Nordisk paid $725 million upfront to Sofinnova for the Waltham, Mass.-based Corvidia, a company focused on the development of transformational therapies for cardio-renal diseases.

The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.

Corvidia Therapeutics Inc., a clinical stage biotechnology company, announced today the initiation of patient screening for a Phase 2b dose-finding study of ziltivekimab

Ablexis grants rights to Corvidia to use the AlivaMab Mouse™ platform for research, development and potential commercialization of antibodies